UMKC School of Medicine researcher Paula Monaghan Nichols, Ph.D., has received a $867,000 National Institutes of Health grant to look into a treatment that minimizes neurological side effects for a chronic lung disease that affects a significant number of premature babies.

The project is part of a multi-principle investigator initiated proposal between Monaghan Nichols, Dr. Venkatesh Sampath from Children’s Mercy Hospital Kansas City, and Dr. Donald DeFranco at the University of Pittsburgh School of Medicine, Pennsylvania, that totals more than $3 million in NIH funding over a 5-year period.

The research will explore the use of Ciclesonide (CIC), an inhaled steroid currently used to treat asthma, as an alternate therapy for bronchopulmonary dysplasia (BPD). BDP causes tissue damage in the tiny air sacs of the lung leading to severe respiratory distress. It is often the result premature birth and mechanical oxygen ventilation. The disease touches nearly seven of 10 infants born before 28 weeks of gestation. In the United States, that is an estimated 10,000 to 15,000 babies a year.

There is currently no cure for BPD but clinical treatments to limit inflammation and the progression of BPD include long-acting synthetic drugs such as dexamethasone. Those drugs, however, also come with a significant risk of adverse effects on a child’s systemic growth and neurodevelopment that can lead to long-lasting changes in brain structure and function.

Monaghan Nichols, associate dean for research, professor and chair of Biomedical Sciences, said infants that acquire BPD face significant mortality rates. Survivors often have recurrent hospital visits, need for respiratory therapies and persistent limitations in pulmonary function.

“Therefore, there remains a need for a pharmacotherapy for BPD in neonates that will have beneficial anti-inflammatory and lung maturation effects, but limited adverse neurological side effects,” Monaghan Nichols said.

Preliminary studies have found that Ciclesonide, even with intermittent doses, can suppress acute lung inflammation with limited neurological alterations in rat models.

“Given the established safety of CIC in very young children, the clinical translation of our proposed studies to human neonates could be expedited, particularly given the limited, safe and effective therapeutic options available for treating or preventing BPD in susceptible premature infants,” Monaghan Nichols said.